Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case–control study

References

• Ito K, Piantham C, Nishiura H. Relative instantaneous reproduction number of Omicron SARS-CoV-2 variant with respect to the delta variant in Denmark. J Med Virol. 2022;94(5):2265–2268.
   PubMed Web of Science ®Google Scholar
• HKSAR Government. Latest situation of reported cases of COVID-19 in Hong Kong 2022 [16 April 2022]. Available from: http://www.chp.gov.hk/files/misc/latest_situation_of_reported_cases_covid_19_eng.csv
   Google Scholar
• Taylor L. COVID-19: Hong Kong reports world’s highest death rate as zero COVID strategy fails. Br Med J. 2022;376:o707.
   PubMedGoogle Scholar
• World Health Organisation. WHO Coronavirus (COVID-19) Dashboard 2022 [23 April 2022]. Available from: https://covid19.who.int/
   Google Scholar
• Frenck RW J, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents. N Engl J Med. 2021;385(3):239–250.
   PubMed Web of Science ®Google Scholar
• Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819–1829.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
   PubMed Web of Science ®Google Scholar
• Thompson MG, Stenehjem E, Grannis S, et al. Effectiveness of COVID-19 vaccines in ambulatory and inpatient care settings. N Engl J Med. 2021;385(15):1355–1371.
   PubMed Web of Science ®Google Scholar
• Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar. N Engl J Med. 2022;386(19):1804–1816.
   PubMed Web of Science ®Google Scholar
• Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and delta variants. JAMA. 2022;327(7):639–651.
   PubMed Web of Science ®Google Scholar
• Andrews N, Stowe J, Kirsebom F, et al. COVID-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022;386(16):1532–1546.
   PubMed Web of Science ®Google Scholar
• Mesfin Y, Chen D, Bond H, et al. Epidemiology of infections with SARS-CoV-2 Omicron BA. 2 variant in Hong Kong, January-March 2022. Emerg Infect Dis. 2022;28(9):1856–1858.
   PubMed Web of Science ®Google Scholar
• Rahimi F, Abadi ATB. The Omicron subvariant BA. 2: birth of a new challenge during the COVID-19 pandemic. Int J Surg. 2022;99:Article 106261.
   Web of Science ®Google Scholar
• Jara A, Undurraga EA, González C, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. New Engl J Med. 2021;385(10):875–884.
   PubMed Web of Science ®Google Scholar
• Cerqueira-Silva T, Andrews JR, Boaventura VS, et al. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26. COV2. S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. The Lancet Infect Dis. 2022;22(6):791–801.
   PubMed Web of Science ®Google Scholar
• Kang M, Yi Y, Li Y, et al. Effectiveness of inactivated COVID-19 vaccines against illness caused by the B. 1.617. 2 (delta) variant during an outbreak in Guangdong, China: A cohort study. Ann Intern Med. 2022;175(4):533–540.
   PubMed Web of Science ®Google Scholar
• Lim WW, Mak L, Leung GM, et al. Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. The Lancet Microbe. 2021;2(9):e423.
   PubMedGoogle Scholar
• Mallapaty S. China’s COVID vaccines have been crucial — now immunity is waning. Nature. 2021;598(7881):398–399.
   PubMed Web of Science ®Google Scholar
• Wan EYF, Chui CSL, Lai FTT, et al. Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. Lancet Infect Dis. 2021;21:00451–00455.
   Google Scholar
• Chua GT, Kwan MYW, Chui CSL, et al. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents following comirnaty vaccination. Clin Infect Dis. 2021:ciab989.
   Web of Science ®Google Scholar
• Li X, Tong X, Yeung WWY, et al. Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong. Ann Rheum Dis. 2021;81(4):564–568.
   PubMed Web of Science ®Google Scholar
• Lai FTT, Huang L, Chui CSL, et al. Multimorbidity and adverse events of special interest associated with COVID-19 vaccines in Hong Kong. Nat Commun. 2022;13(1):1–8.
   PubMed Web of Science ®Google Scholar
• Lai FTT, Li X, Peng K, et al. Carditis after COVID-19 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac): a case-control study. Ann Intern Med. 2022;175(3):362–370.
   PubMed Web of Science ®Google Scholar
• Lai FTT, Huang L, Peng K, et al. Post-COVID-19-vaccination adverse events and healthcare utilization among individuals with or without previous SARS-CoV-2 infection. J Intern Med. 2022;291(6):864–869.
   PubMed Web of Science ®Google Scholar
• Li X, Tong X, Wong ICK, et al. Lack of inflammatory bowel disease flare-up following two-dose BNT162b2 vaccine: a population-based cohort study. Gut. 2022:gutjnl-2021-326860.
   Web of Science ®Google Scholar
• Wan EYF, Chui CSL, Wang Y, et al. Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: A self-controlled case series and nested case-control study. The Lancet Regional Health – Western Pacific. 2022;21:100393.
   PubMedGoogle Scholar
• Xiong X, Wong CKH, Au ICH, et al. Safety of inactivated and mRNA COVID-19 vaccination Among patients treated for hypothyroidism: A population-based cohort study. Thyroid. 2022;32(5):505–514.
   PubMed Web of Science ®Google Scholar
• HKSAR Government. Third dose COVID-19 vaccination arrangements for persons under certain groups 2021 [3 November 2021]. Available from: https://www.info.gov.hk/gia/general/202111/03/P2021110300536.htm
   Google Scholar
• HKSAR Government. Further expansion of COVID-19 vaccination arrangements from January 1 2021 [24 December 2021]. Available from: https://www.info.gov.hk/gia/general/202112/24/P2021122400509.htm
   Google Scholar
• Charlson ME, Groll D, To T, et al. Charlson comorbidity index. Nurs Res (New York). 2013;62(1):2.
   Google Scholar
• Thompson MG, Burgess JL, Naleway AL, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers - eight U.S. locations, December 2020-march 2021. MMWR Morb Mortal Wkly Rep. 2021;70(13):495–500.
   PubMed Web of Science ®Google Scholar
• Tanriover MD, Doğanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213–222.
   PubMed Web of Science ®Google Scholar
• Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med. 2021;385(24):e83.
   PubMed Web of Science ®Google Scholar
• McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong. Lancet Infect Dis. 2022 Jul 15. S1473-3099(22)00345-0.
   Web of Science ®Google Scholar
• Andrews N, Stowe J, Kirsebom F, et al. COVID-19 vaccine effectiveness against the Omicron (B. 1.1. 529) variant. N Engl J Med. 2022;386(16):1532–1546.
   PubMed Web of Science ®Google Scholar
• Price AM, Olson SM, Newhams MM, et al. BNT162b2 protection against the Omicron variant in children and adolescents. N Engl J Med. 2022;386(20):1899–1909.
   PubMed Web of Science ®Google Scholar
• Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA vaccines against, COVID-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. Br Med J. 2022;376:e069761.
   PubMedGoogle Scholar
• Nemet I, Kliker L, Lustig Y, et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. N Engl J Med. 2022;386(5):492–494.
   PubMed Web of Science ®Google Scholar
• Premikha M, Chiew CJ, Wei WE, et al. Comparative effectiveness of mRNA and inactivated whole virus vaccines against COVID-19 infection and severe disease in Singapore. Clin Infect Dis. 2022:ciac288.
   PubMed Web of Science ®Google Scholar
• Moderbacher CR, Ramirez SI, Dan JM, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183(4):996–1012. e19.
   PubMed Web of Science ®Google Scholar
• Peng Q, Zhou R, Wang Y, et al. Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. EBioMedicine. 2022;77:Article 103904.
   PubMed Web of Science ®Google Scholar
• Lai KT-W, Lai Wan Loong EY-T, Fung TL-H, et al. Safety and immunogenicity of a booster vaccination by CoronaVac or BNT162b2 in previously two-dose inactivated virus vaccinated individuals with negative neutralizing antibody. Vaccines (Basel). 2022;10(4):556.
   PubMed Web of Science ®Google Scholar
• Vályi-Nagy I, Matula Z, Gönczi M, et al. Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans. GeroScience. 2021;43(5):2321–2331.
   PubMed Web of Science ®Google Scholar
• Matula Z, Gönczi M, Bekő G, et al. Antibody and T cell responses against SARS-CoV-2 elicited by the third dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines using a homologous or heterologous booster vaccination strategy. Vaccines (Basel). 2022;10(4):539.
   PubMed Web of Science ®Google Scholar
• Yuan J, Lam WWT, Xiao J, et al. Why do Chinese older adults in Hong Kong delay or refuse COVID-19 vaccination? A qualitative study based on grounded theory 2022 [27 April 2022]. Available from: PREPRINT (version 2) available at Research Square. doi:10.21203/rs.3.rs-1569282/v2.
   Google Scholar
• HKSAR Government. COVID-19 vaccination walk-in service of DH's Elderly Health Centres to expand starting next Monday 2022 [7 January 2022]. Available from: https://www.info.gov.hk/gia/general/202201/07/P2022010700268.htm.
   Google Scholar
• Government of the People's Republic of China. Vaccine campaign to focus on seniors 2022 [19 March 2022]. Available from: http://english.www.gov.cn/statecouncil/ministries/202203/19/content_WS62353282c6d02e5335327fb1.html
   Google Scholar
• Cheng SM, Mok CKP, Chan KC, et al. SARS-CoV-2 omicron variant BA. 2 neutralisation in sera of people with comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020–2022. Eurosurveillance. 2022;27(18):2200178.
   Web of Science ®Google Scholar